MYC and Miyoshi myopathy: On this basis, we indeed demonstrated that miR-22 and lenalidomide combination exerts synergistic antiproliferative activity, together with their combined effects on MYC, offering proof-of-concept for a new therapeutic approach, especially in IMiD-refractory MM patients.